Skip to content
Screener

Organon OGN Other Respiratory — Revenue

Other product segments

Nexplanon/Implanon NXT
$201M-19.0%
Other
$87M+11.5%
Zetia
$87M+2.4%
Atozet
$85M+10.4%
Other Non-Opiod Pain, Bone and Dermatology
$68M0.0%
Hadlima
$67M+42.6%
Nasonex
$65M-9.7%
Follistim AQ
$61M-11.6%
Arcoxia
$59M-4.8%
Cozaar/Hyzaar
$57M+3.6%
Renflexis
$57M0.0%
Emgality
$54M+68.8%
Other Women's Health
$46M+7.0%
Singulair
$40M-45.9%
Diprospan
$35M+16.7%
Dulera
$35M-18.6%
Clarinex
$31M-8.8%
Propecia
$30M+15.4%
Fosamax
$29M-12.1%
Other Cardiovascular
$28M-6.7%
Ganirelix Acetate Injection
$26M-3.7%
Marvelon/Mercilon
$26M-33.3%
Proscar
$26M+8.3%
Vtama
$25M+4.2%
NuvaRing
$24M+9.1%
Other Biosimilars
$24M
Vytorin
$21M-8.7%
Brenzys
$20M+42.9%
Rosuzet
$6M+50.0%
Jada
$5M-66.7%
Ontruzant
$5M-72.2%

Similar metrics at other companies

Lennar logo
LENOther revenues — Revenue
$331.4M-6.8%
PROG Holdings logo
PRGOther Revenues — Revenue
$21.62M+165%
Flanigan's Enterprises logo
BDLOther Revenues — Revenue
$88K+27.5%
United Rentals logo
URIServiceand Other Revenues — Revenue
$101M+6.3%
Flywire Corporation logo
FLYWPlatform And Other Revenues — Revenue
$31.85M+1.7%
Coinbase Global, Inc. logo
COINOther revenue — Revenue
$73.63M-24.5%

Other financials

Income statement

See full
Revenue$1.5B-3.5%
Gross profit$783.0M-6.9%
Net income$146.0M+67.8%
EPS (diluted)$0.55+66.7%

Balance sheet

See full
Cash & equivalents$1.1B+104%
Total debt$8.6B-4.3%
Total equity$903.0M+66.6%
Total assets$13.0B-1.2%

Cash flow

See full
Operating cash flow$225.0M+200%
CapEx$37.0M+15.6%
Free cash flow$188.0M+337%

Valuation

See full
Market cap$3.56B+57.0%
Enterprise value$11.01B+4.2%
P/E6.6×+2.1×
P/S0.6×+0.2×

Profitability

See full
Gross margin52.8%-4.4pp
Net margin8%-12.3pp
FCF margin11.1%-1.3pp

Returns & leverage

See full
Return on equity71.6%
Debt / equity9.5×-7.0×
Current ratio+0.3×

Where this comes from

Reported directly by Organon in its filing.

Tagged under the XBRL concept us-gaap:Revenues.

The source filing: Organon’s 10-Q, filed May 4, 2026.

Filed
May 4, 2026, 8:46 AM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001628280-26-029532
($ in millions)Three Months Ended March 31, 2025 / U.S.2025 / Int’lTotalU.S.Int’lTotal
Nasonex65657172
Dulera231235341043
Clarinex130313434
Other Respiratory (1)1111210313
Non-Opioid Pain, Bone and Dermatology
Arcoxia59596262
Fosamax292913233
Diprospan35353030

Item 1. Financial Statements (unaudited)

FAQ

What is Organon's other respiratory — revenue?
Organon (OGN) reported other respiratory — revenue of $12M in Q1 2026.
How has Organon's other respiratory — revenue changed year-over-year?
Organon's other respiratory — revenue decreased by 7.7% year-over-year, from $13M to $12M.
What is the long-term trend for Organon's other respiratory — revenue?
Over 4 years (2021 to 2025), Organon's other respiratory — revenue has grown at a -12.7% compound annual growth rate (CAGR), from $88M to $51M.
What does other respiratory — revenue mean?
This metric represents the total net sales generated from the company's portfolio of respiratory-related pharmaceutical products outside of its primary focus areas. It serves as an indicator of the revenue contribution and lifecycle stage of legacy or non-core respiratory assets within the broader product mix. Monitoring this figure helps investors assess the impact of portfolio rationalization and the performance of established therapeutic treatments.

Ask your AI about Organon's other respiratory — revenue.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude